Test Bank for Saunders Comprehensive Review for the NCLEX-RN® Examination, 9th Edition by Linda Anne Silvestri and Angela Silvestri Complete Questions and Answers Pass Guaranteed

SILVESTRI TEST BANK: SAUNDERS COMPREHENSIVE REVIEW FOR THE
Silvestri: Saunders Comprehensive Review for the NCLEX-RN@
Examination, 9th NCLEX Edition-RN EXAMINATION 9th EDITION
PharmacologyI

TestIBank

MULTIPLEICHOICE

1. TheInurseIisIcaringIforIaIclientIinIlabor.ITheInurseIreviewsItheIphysician’sIprescriptionsIandInotesIthatIth
eIclientIhasIaIprescriptionIforIbutorphanolItartrateI(Stadol).ITheInurseIunderstandsIthatIthisImedicationIisI
prescribedIfor:
1. PainIrelief
2. IncreasingIuterineIcontractions
3. DecreasingIuterineIcontractions
4. PromotingIfetalIlungImaturity

ANS:I I 1

Rationale:ITheIclientIinIlaborImayIbeIgivenIparenteralIanalgesiaIduringItheIfirstIstageIofIlabor,IupItoI2ItoI3
IhoursIbeforeItheIanticipatedIdelivery.IButorphanolItartrate IisIaImedicationIthatImayIbeIprescribedIforIpai
nIrelief.I“IncreasingIuterineIcontractions,”I“decreasingIuterineIcontractions,”IandI“promotingIfetalIlungIm
aturity”IareInotIactionsIofIthisImedication.

Test-
TakingIStrategy:IKnowledgeIofItheIactionIofIbutorphanolItartrateIisIrequiredItoIanswerIthisIquestion.IRe
memberIthatIthisImedicationIisIusedIforIpainIrelief.IReviewItheIactionIofIthisImedicationIifIyouIhadIdifficu
ltyIwithIthisIquestionIandIareIunfamiliarIwithIthisImedication.

PTS: 1
DIF: LevelIofICognitiveIAbility:IUnderstanding
REF:
Lehne,IR.I(2010).IPharmacologyIforInursingIcareI(7thIed.).ISt.ILouis:ISaunders.I
OBJ: ClientINeeds:IPhysiologicalIIntegrity
TOP: ContentIArea:IPharmacology
MSC:I IntegratedIProcess:INursingIProcess—Planning

2. TheIpostpartumInurseIisIcaringIforIaIclientIwithIanIepiduralIcatheterIinIplaceIforIopioidIanalgesicIa
dministrationIfollowingIcesareanIbirth.IIfItheIclientIdevelopsIrespiratoryIdepressionIandIrequiresIn
aloxoneI(Narcan)IasIanIantidote,ItheIclientImayIcomplainIofIwhichIofItheIfollowing?
1. IncreaseIinIherIpainIlevel
2. DecreaseIinIherIpainIlevel
3. IncreaseIinItheIamountIofIitchingIfromItheIopioidIusedIinItheIepidural
4. DecreaseIinItheIamountIofIitchingIfromItheIopioidIusedIinItheIepidural

, ANS:I I 1

Rationale:IRememberIthatIopioidsIareIusedIforIepiduralIanalgesia.INaloxoneIisIanIopioidIantagonist,Iwhi
chIreversesItheIeffectsIofIopioids.IIfIitIisIgiven,ItheIclientImayIcomplainIofIanIincreaseIinIherIpainIlevel.IT
hereforeI“decreaseIinIherIpainIlevel,”I“increaseIinItheIamountIofIitchingIfromItheIopioidIusedIinItheIepidu
ral,”IandI“decreaseIinItheIamountIofIitchingIfromItheIopioidIusedIinItheIepidural”IareIincorrect.

Test-
TakingIStrategy:IToIanswerIthisIquestionIaccurately,IyouImustIknowIthatIopioidIanalgesicsIareItheImedica
tionsIusedIwithIepiduralIanalgesiaItoIrelieveIpain.IThereforeIifInaloxoneIisIadministeredIasIanIantidoteIfor
IanIopioidIanalgesic,ItheIclient’sIpainIwillIincrease.IReviewItheIeffectsIofInaloxoneIifIthisIquestionIwasIdif
ficult.

PTS: 1
DIF: LevelIofICognitiveIAbility:IUnderstanding
REF:
Lehne,IR.I(2010).IPharmacologyIforInursingIcareI(7thIed.).ISt.ILouis:ISaunders.I
OBJ: ClientINeeds:IPhysiologicalIIntegrity
TOP: ContentIArea:IPharmacology
MSC:I IntegratedIProcess:INursingIProcess—Assessment

3. AIclientIexperiencingIpretermIlaborIatItheItwenty-
ninthIweekIofIgestationIhasIbeenIadmittedItoItheIhospital.ITheIclientIhasIaIprescriptionItoIreceiveIbetame
thasoneI(Celestone).ITheInurseIunderstandsIthatItheImedicationIwillIdoIwhichIofItheIfollowing?
1. PreventIspontaneousIdelivery.
2. StopItheIuterineIcontractions.
3. PromoteImaturationIofItheIfetalIlungs.
4. AccelerateItheIgrowthIrateIofItheIfetus.

ANS:I I 3

Rationale:IBetamethasoneI(Celestone)IisIclassifiedIasIanIanti-
inflammatoryIandIcorticosteroid.IItIincreasesItheIsurfactantIlevelIandIlungImaturityIinItheIfetus,IwhichIre
ducesItheIincidenceIofIrespiratoryIdistressIsyndrome.IDeliveryImustIbeIdelayedIforIatIleastI48IhoursIafterI
administrationIofIbetamethasoneItoIallowItimeIforItheIlungsIofItheIfetusItoImature.

Test-
TakingIStrategy:IOptionsIthatIareIcomparableIorIalikeIareInotIlikelyItoIbeIcorrect.IWithIthisIinImind,Ielim
inateI“preventIspontaneousIdelivery”IandI“stopItheIuterineIcontractions.”INoteItheIstrategicIwordsI“twent
y-
ninthIweekIofIgestation.”ISpecificIknowledgeIaboutItheImedicationIandIknowledgeIofItheIproblemsIencou
nteredIbyIprematureIinfantsIwillIassistIinIansweringIthisIquestion.IReviewItheIactionIofIthisImedicationIifI
thisIquestionIwasIdifficult.

PTS: 1
DIF: LevelIofICognitiveIAbility:IUnderstanding
REF: McKinney,IE.,IJames,IS.,IMurray,IS.,I&IAshwill,IJ.I(2009).IMaternal-
childInursingI(3rdIed.).ISt.ILouis:ISaunders. OBJ: ClientINeeds:IPhysiologicalIIntegrity

, TOP: ContentIArea:IPharmacology
MSC:I IntegratedIProcess:INursingIProcess—Planning

4. AIclientIwithIpreeclampsiaIisIreceivingImagnesiumIsulfate.ITheInurseIassessesItheIclientIcloselyIforI
whichIsignIofImagnesiumItoxicity?
1. Proteinuria
2. HyperactiveIdeepItendonIreflexes
3. RespiratoryIrateIofI10Ibreaths/min
4. SerumImagnesiumIlevelIofI5ImEq/L

ANS:I I 3

Rationale:IMagnesiumItoxicityIisIaIriskIassociatedIwithImagnesiumIsulfateItherapy.ISignsIofImagnesiumIt
oxicityIrelateItoIcentralInervousIsystemI(CNS)IdepressionIandIincludeIrespiratoryIdepression,IlossIofIdeep
ItendonIreflexes,IandIsuddenIdropIinIfetalIheartIrateIand/orImaternalIheartIrateIandIbloodIpressure.
MagnesiumIisIexcretedIthroughItheIkidneys.IIfIrenalIimpairmentIisIpresent,ImagnesiumItoxicityIcanIdevel
opIveryIquickly.ITherapeuticIserumIlevelsIofImagnesiumIareI4ItoI7ImEq/L.

Test-
TakingIStrategy:IToIanswerIthisIquestionIaccurately,IyouImustIrecallIthatImagnesiumIsulfateIisIaICNSIde
pressant.IBeginItoIanswerIthisIquestionIbyIeliminatingI“proteinuria”IandI“hyperactiveIdeepItendonIreflex
es,”IwhichIareIsignsIofIpreeclampsia.ISelectIbetweenItheIlastItwoIoptionsIusingImedicationIknowledgeIan
dIrecallingIthatItheItherapeuticIserumIlevelsIofImagnesiumIareI4ItoI7ImEq/L.IReviewIthisImedicationIandI
theInormalImagnesiumIlevelIifIthisIquestionIwasIdifficult.

PTS: 1
DIF: LevelIofICognitiveIAbility:IAnalyzing
REF: Lowdermilk,ID.,IPerry,IS.,I&ICashion,IK.I(2010).IMaternityInursingI(8thIed.).ISt.ILouis:IMosby.
OBJ:
ClientINeeds:IPhysiologicalIIntegrityITOP:
ContentIArea:IPharmacology
MSC:I IntegratedIProcess:INursingIProcess—Assessment

5. AIpregnantIclientIwhoIhasIhumanIimmunodeficiencyIvirusI(HIV)IinfectionIisIbeingIseenIinItheIantenatalI
clinic.ITheInurseIrecallsIthatIzidovudineI(AZT)ItherapyIwillIbeIinitiatedIwhenItheIfetusIhasIreachedIhowI
manyIweeksIofIgestation?
1. 4
2. 14
3. 24
4. 34

ANS:I I 2

Rationale:ITheIpregnantIwomenIwithIHIVIinfectionIwillIbeIprescribedIoralIAZTIinItheIfourteenthIweekIo
fIgestation.IBeforeIthisItime,ItheIfetusIisIatIriskIbecauseIofItheIteratogenicIeffectsIofItheImedication.IIn

, addition,IaIbolusIofIAZTIisIgivenIintravenouslyIduringIlabor,IandItheIneonateIisItreatedIforIsixIweeksIafter
Ibirth.


Test-
TakingIStrategy:IToIanswerIthisIquestionIaccurately,IyouImustIbeIfamiliarIwithIpharmacologicalItherapyI
forIclientsIwhoIareIHIV-
positive.IKnowingIthatItheIfetusIisImostIvulnerableItoItheIeffectsIofImedicationsIandIchemicalsIduringIthe
IperiodIofIorganogenesisIwillIassistIyouIinIselectingItheIcorrectIanswer.IReviewItreatment ImeasuresIforIth
eIpregnantIclientIwithIHIVIinfectionIifIyouIhadIdifficultyIwithIthisIquestion.

PTS: 1
DIF: LevelIofICognitiveIAbility:IUnderstanding
REF:
Lehne,IR.I(2010).IPharmacologyIforInursingIcareI(7thIed.).ISt.ILouis:ISaunders.I
OBJ: ClientINeeds:IPhysiologicalIIntegrity
TOP: ContentIArea:IPharmacology
MSC:I IntegratedIProcess:INursingIProcess—Planning

6. TheInurseIhasIaIroutineIprescriptionItoIinstillIerythromycinIointmentI(Ilotycin)IintoItheIeyesIofIaI
newborn.ITheInurseIplansItoIexplainItoItheIparentsIthatItheIpurposeIofItheImedicationIisIto:
1. HelpItheInewbornItoIseeImoreIclearly.
2. GuardIagainstIinfectionIacquiredIduringIintrauterineIlife.
3. EnsureItheIsterilityIofItheIconjunctivaIinItheInewborn.
4. ProtectItheInewbornIfromIcontractingIanIeyeIinfectionIduringIbirth.

ANS:I I 4

Rationale:ITheIuseIofIeyeIprophylaxisIwithIanIagentIsuchIasIerythromycinIprotectsItheInewbornIfromIcon
tractingIaIconjunctivalIinfectionIduringIbirth.IThisIinfection,IcalledIophthalmiaIneonatorum,IresultsIfromI
maternalIvaginalIinfectionIwithIchlamydiaIorIgonorrhea.IThisIprophylaxisIisImandatoryIinItheIUnitedIStat
es.I“HelpItheInewbornItoIseeImoreIclearly,”I“guardIagainstIinfectionIacquiredIduringIintrauterineIlife,”Ian
dI“ensureItheIsterilityIofItheIconjunctivaIinItheInewborn”IdoInotIdescribeItheIpurposesIofIthisImedication.

Test-
TakingIStrategy:IFamiliarityIwithItheIpurposeIofIthisImedicationIisIneededItoIanswerIthisIquestion.IReme
mberIerythromycinIprotectsItheInewbornIfromIcontractingIaIconjunctivalIinfectionIduringIbirth.
ReviewItheIpurposeIofIthisImedicationIifIyouIhadIdifficultyIwithIthisIquestion.

PTS: 1
DIF: LevelIofICognitiveIAbility:IApplying
REF:
Lehne,IR.I(2010).IPharmacologyIforInursingIcareI(7thIed.).ISt.ILouis:ISaunders.I
OBJ: ClientINeeds:IHealthIPromotionIandIMaintenance
TOP: ContentIArea:IPharmacology
MSC:I IntegratedIProcess:ITeachingIandILearning

7. TheInurseIhasIaIroutineIprescriptionItoIadministerIanIinjectionIofIphytonadioneI(vitaminIK)ItoItheI
newborn.IBeforeIgivingItheImedication,ItheInurseIexplainsItoItheIclientIthatIthisImedicationIwill: